Genomic and epigenomic biomarkers in colorectal cancer: From diagnosis to therapy.

ABSTRACT: Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in the United States. Despite ongoing efforts aimed at increasing screening for CRC and early detection, and development of more effective therapeutic regimens, the overall morbidity and mortality from this malignancy remains a clinical challenge. Therefore, identifying and developing genomic and epigenomic biomarkers that can improve CRC diagnosis and help predict response to current therapies are of paramount importance for improving survival outcomes in CRC patients, sparing patients from toxicity associated with current regimens, and reducing the economic burden associated with these treatments. Although efforts to develop biomarkers over the past decades have achieved some success, the recent availability of

SUBMITTER: Ruiz-Banobre J 

PROVIDER: S-EPMC10338180 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature